Immunohistochemical Profile of Endometrial Adenocarcinoma: A Study of 61 Cases and Review of the Literature
The differences in immunohistochemical expression of p53, bcl-2, bax, estrogen receptor (ER), and progesterone receptor (PR) were evaluated in 40 endometrioid and 21 papillary serous carcinomas of endometrium and correlated with known predictors of survival, such as grade and stage. Uterine papillar...
Gespeichert in:
| Veröffentlicht in: | Modern pathology 2000-04, Vol.13 (4), p.379-388 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 388 |
|---|---|
| container_issue | 4 |
| container_start_page | 379 |
| container_title | Modern pathology |
| container_volume | 13 |
| creator | Kounelis, Sophia Kapranos, Nikiforos Kouri, Efi Coppola, Domenico Papadaki, Helen Jones, Mirka W |
| description | The differences in immunohistochemical expression of p53, bcl-2, bax, estrogen receptor (ER), and progesterone receptor (PR) were evaluated in 40 endometrioid and 21 papillary serous carcinomas of endometrium and correlated with known predictors of survival, such as grade and stage. Uterine papillary serous adenocarcinomas (UPSA) showed significantly higher p53 expression than did uterine endometrioid adenocarcinomas (UEA) (76.2% versus 35%), whereas both ER and PR were more often positive in endometrioid than in serous tumors (p =.005 and.0005). No significant difference was found in bcl-2 and bax expression between both histologic types. However, there was definite decrease in intensity of bcl-2 in UPSA compared with UEA. In endometrioid carcinoma, p53 overexpression was associated with high-grade and advanced-stage tumors (p =.0006 and.006), whereas ER and PR expression was associated with low-grade and early-stage tumors (p =.0006 and.0001; p =.003 and.0006). Bcl-2 immunopositivity was more common in low-grade, early-stage rather than in high-grade, advanced-stage adenocarcinomas, but the difference was not statistically significant (p =.24 and.07). Bax immunopositivity was associated with well-differentiated (p =.04) and early-stage tumors. Furthermore, a significant inverse relationship between bax and p53 reactivity was defined (p =.05), especially in tumors of endometrioid type. Bax and PR immunoexpression correlated near the limit of statistical significance (p =.08), whereas no relationship was found among bax, bcl-2, and ER immunopositivity. Our results indicate that the differences in immunohistochemical profiles of endometrioid and serous carcinomas support the existence of different molecular pathways of their development. The correlation of immunohistochemical findings with histologic grade and clinical stage could help in predicting biologic behavior and planning treatment in patients who are diagnosed as having these tumors. |
| doi_str_mv | 10.1038/modpathol.3880062 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71072318</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0893395222040431</els_id><sourcerecordid>998331381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c550t-a3f6043d07d33206eb828df69674451efd7ea603a61eacd90ad44df7e0023d713</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS1ERYfCA7AARSzYpVzbieOB1WhUaKWRivhZW659w7gk9tR2QH17PGTUoi66snTvd47tcwh5ReGUApfvx2B3Om_DcMqlBBDsCVnQlkMNTLZPyQLkktd82bJj8jylawDatJI9I8cUOikk8AX5dTGOkw9bl3IwWxyd0UP1JYbeDViFvjrzNoyYoyvjlUUfjI7G-TDqD9Wq-pYne7vHBK3WOmGqtLfVV_zt8M9-nLdYbVzGqPMU8QU56vWQ8OXhPCE_Pp19X5_Xm8vPF-vVpjZtC7nWvBfQcAud5ZyBwCvJpO3FUnRN01LsbYdaANeCojZ2Cdo2je07BGDcdpSfkHez7y6GmwlTVqNLBodBewxTUl35PuNUFvDtA_A6TNGXtynGKG14J9oC0RkyMaQUsVe76EYdbxUFta9B3dWgDjUUzZuD8XQ1ov1PMedeADYDqaz8T4z3Nz_m-noW-X9x3rne7z_OeyzhlgqiSsahN2hdRJOVDe4R979EErS_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>221143765</pqid></control><display><type>article</type><title>Immunohistochemical Profile of Endometrial Adenocarcinoma: A Study of 61 Cases and Review of the Literature</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Kounelis, Sophia ; Kapranos, Nikiforos ; Kouri, Efi ; Coppola, Domenico ; Papadaki, Helen ; Jones, Mirka W</creator><creatorcontrib>Kounelis, Sophia ; Kapranos, Nikiforos ; Kouri, Efi ; Coppola, Domenico ; Papadaki, Helen ; Jones, Mirka W</creatorcontrib><description>The differences in immunohistochemical expression of p53, bcl-2, bax, estrogen receptor (ER), and progesterone receptor (PR) were evaluated in 40 endometrioid and 21 papillary serous carcinomas of endometrium and correlated with known predictors of survival, such as grade and stage. Uterine papillary serous adenocarcinomas (UPSA) showed significantly higher p53 expression than did uterine endometrioid adenocarcinomas (UEA) (76.2% versus 35%), whereas both ER and PR were more often positive in endometrioid than in serous tumors (p =.005 and.0005). No significant difference was found in bcl-2 and bax expression between both histologic types. However, there was definite decrease in intensity of bcl-2 in UPSA compared with UEA. In endometrioid carcinoma, p53 overexpression was associated with high-grade and advanced-stage tumors (p =.0006 and.006), whereas ER and PR expression was associated with low-grade and early-stage tumors (p =.0006 and.0001; p =.003 and.0006). Bcl-2 immunopositivity was more common in low-grade, early-stage rather than in high-grade, advanced-stage adenocarcinomas, but the difference was not statistically significant (p =.24 and.07). Bax immunopositivity was associated with well-differentiated (p =.04) and early-stage tumors. Furthermore, a significant inverse relationship between bax and p53 reactivity was defined (p =.05), especially in tumors of endometrioid type. Bax and PR immunoexpression correlated near the limit of statistical significance (p =.08), whereas no relationship was found among bax, bcl-2, and ER immunopositivity. Our results indicate that the differences in immunohistochemical profiles of endometrioid and serous carcinomas support the existence of different molecular pathways of their development. The correlation of immunohistochemical findings with histologic grade and clinical stage could help in predicting biologic behavior and planning treatment in patients who are diagnosed as having these tumors.</description><identifier>ISSN: 0893-3952</identifier><identifier>EISSN: 1530-0285</identifier><identifier>DOI: 10.1038/modpathol.3880062</identifier><identifier>PMID: 10786803</identifier><identifier>CODEN: MODPEO</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>Adenocarcinoma - metabolism ; Adenocarcinoma - pathology ; Apoptosis ; bax ; bcl-2 ; bcl-2-Associated X Protein ; Cancer therapies ; Cell death ; Cell growth ; Cystadenocarcinoma, Papillary - metabolism ; Cystadenocarcinoma, Papillary - pathology ; Endometrial adenocarcinoma ; Endometrial cancer ; Endometrial Neoplasms - metabolism ; Endometrial Neoplasms - pathology ; Endometrioid ; Endometrium ; Estrogens ; Female ; Humans ; Hyperplasia ; Immunohistochemistry ; Laboratory Medicine ; Medical prognosis ; Medicine ; Medicine & Public Health ; Neoplasm Staging ; original-article ; p53 ; Papillary serous ; Pathology ; Proteins ; Proto-Oncogene Proteins - analysis ; Proto-Oncogene Proteins c-bcl-2 - analysis ; Receptors, Estrogen - analysis ; Receptors, Progesterone - analysis ; Tumor Suppressor Protein p53 - analysis ; Tumors ; Uterine Neoplasms - metabolism ; Uterine Neoplasms - pathology</subject><ispartof>Modern pathology, 2000-04, Vol.13 (4), p.379-388</ispartof><rights>2000 United States & Canadian Academy of Pathology</rights><rights>The United States and Canadian Academy of Pathology, Inc. 2000</rights><rights>Copyright Nature Publishing Group Apr 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c550t-a3f6043d07d33206eb828df69674451efd7ea603a61eacd90ad44df7e0023d713</citedby><cites>FETCH-LOGICAL-c550t-a3f6043d07d33206eb828df69674451efd7ea603a61eacd90ad44df7e0023d713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/221143765?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10786803$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kounelis, Sophia</creatorcontrib><creatorcontrib>Kapranos, Nikiforos</creatorcontrib><creatorcontrib>Kouri, Efi</creatorcontrib><creatorcontrib>Coppola, Domenico</creatorcontrib><creatorcontrib>Papadaki, Helen</creatorcontrib><creatorcontrib>Jones, Mirka W</creatorcontrib><title>Immunohistochemical Profile of Endometrial Adenocarcinoma: A Study of 61 Cases and Review of the Literature</title><title>Modern pathology</title><addtitle>Mod Pathol</addtitle><addtitle>Mod Pathol</addtitle><description>The differences in immunohistochemical expression of p53, bcl-2, bax, estrogen receptor (ER), and progesterone receptor (PR) were evaluated in 40 endometrioid and 21 papillary serous carcinomas of endometrium and correlated with known predictors of survival, such as grade and stage. Uterine papillary serous adenocarcinomas (UPSA) showed significantly higher p53 expression than did uterine endometrioid adenocarcinomas (UEA) (76.2% versus 35%), whereas both ER and PR were more often positive in endometrioid than in serous tumors (p =.005 and.0005). No significant difference was found in bcl-2 and bax expression between both histologic types. However, there was definite decrease in intensity of bcl-2 in UPSA compared with UEA. In endometrioid carcinoma, p53 overexpression was associated with high-grade and advanced-stage tumors (p =.0006 and.006), whereas ER and PR expression was associated with low-grade and early-stage tumors (p =.0006 and.0001; p =.003 and.0006). Bcl-2 immunopositivity was more common in low-grade, early-stage rather than in high-grade, advanced-stage adenocarcinomas, but the difference was not statistically significant (p =.24 and.07). Bax immunopositivity was associated with well-differentiated (p =.04) and early-stage tumors. Furthermore, a significant inverse relationship between bax and p53 reactivity was defined (p =.05), especially in tumors of endometrioid type. Bax and PR immunoexpression correlated near the limit of statistical significance (p =.08), whereas no relationship was found among bax, bcl-2, and ER immunopositivity. Our results indicate that the differences in immunohistochemical profiles of endometrioid and serous carcinomas support the existence of different molecular pathways of their development. The correlation of immunohistochemical findings with histologic grade and clinical stage could help in predicting biologic behavior and planning treatment in patients who are diagnosed as having these tumors.</description><subject>Adenocarcinoma - metabolism</subject><subject>Adenocarcinoma - pathology</subject><subject>Apoptosis</subject><subject>bax</subject><subject>bcl-2</subject><subject>bcl-2-Associated X Protein</subject><subject>Cancer therapies</subject><subject>Cell death</subject><subject>Cell growth</subject><subject>Cystadenocarcinoma, Papillary - metabolism</subject><subject>Cystadenocarcinoma, Papillary - pathology</subject><subject>Endometrial adenocarcinoma</subject><subject>Endometrial cancer</subject><subject>Endometrial Neoplasms - metabolism</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Endometrioid</subject><subject>Endometrium</subject><subject>Estrogens</subject><subject>Female</subject><subject>Humans</subject><subject>Hyperplasia</subject><subject>Immunohistochemistry</subject><subject>Laboratory Medicine</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasm Staging</subject><subject>original-article</subject><subject>p53</subject><subject>Papillary serous</subject><subject>Pathology</subject><subject>Proteins</subject><subject>Proto-Oncogene Proteins - analysis</subject><subject>Proto-Oncogene Proteins c-bcl-2 - analysis</subject><subject>Receptors, Estrogen - analysis</subject><subject>Receptors, Progesterone - analysis</subject><subject>Tumor Suppressor Protein p53 - analysis</subject><subject>Tumors</subject><subject>Uterine Neoplasms - metabolism</subject><subject>Uterine Neoplasms - pathology</subject><issn>0893-3952</issn><issn>1530-0285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc1u1DAUhS1ERYfCA7AARSzYpVzbieOB1WhUaKWRivhZW659w7gk9tR2QH17PGTUoi66snTvd47tcwh5ReGUApfvx2B3Om_DcMqlBBDsCVnQlkMNTLZPyQLkktd82bJj8jylawDatJI9I8cUOikk8AX5dTGOkw9bl3IwWxyd0UP1JYbeDViFvjrzNoyYoyvjlUUfjI7G-TDqD9Wq-pYne7vHBK3WOmGqtLfVV_zt8M9-nLdYbVzGqPMU8QU56vWQ8OXhPCE_Pp19X5_Xm8vPF-vVpjZtC7nWvBfQcAud5ZyBwCvJpO3FUnRN01LsbYdaANeCojZ2Cdo2je07BGDcdpSfkHez7y6GmwlTVqNLBodBewxTUl35PuNUFvDtA_A6TNGXtynGKG14J9oC0RkyMaQUsVe76EYdbxUFta9B3dWgDjUUzZuD8XQ1ov1PMedeADYDqaz8T4z3Nz_m-noW-X9x3rne7z_OeyzhlgqiSsahN2hdRJOVDe4R979EErS_</recordid><startdate>20000401</startdate><enddate>20000401</enddate><creator>Kounelis, Sophia</creator><creator>Kapranos, Nikiforos</creator><creator>Kouri, Efi</creator><creator>Coppola, Domenico</creator><creator>Papadaki, Helen</creator><creator>Jones, Mirka W</creator><general>Elsevier Inc</general><general>Nature Publishing Group US</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20000401</creationdate><title>Immunohistochemical Profile of Endometrial Adenocarcinoma: A Study of 61 Cases and Review of the Literature</title><author>Kounelis, Sophia ; Kapranos, Nikiforos ; Kouri, Efi ; Coppola, Domenico ; Papadaki, Helen ; Jones, Mirka W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c550t-a3f6043d07d33206eb828df69674451efd7ea603a61eacd90ad44df7e0023d713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adenocarcinoma - metabolism</topic><topic>Adenocarcinoma - pathology</topic><topic>Apoptosis</topic><topic>bax</topic><topic>bcl-2</topic><topic>bcl-2-Associated X Protein</topic><topic>Cancer therapies</topic><topic>Cell death</topic><topic>Cell growth</topic><topic>Cystadenocarcinoma, Papillary - metabolism</topic><topic>Cystadenocarcinoma, Papillary - pathology</topic><topic>Endometrial adenocarcinoma</topic><topic>Endometrial cancer</topic><topic>Endometrial Neoplasms - metabolism</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Endometrioid</topic><topic>Endometrium</topic><topic>Estrogens</topic><topic>Female</topic><topic>Humans</topic><topic>Hyperplasia</topic><topic>Immunohistochemistry</topic><topic>Laboratory Medicine</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasm Staging</topic><topic>original-article</topic><topic>p53</topic><topic>Papillary serous</topic><topic>Pathology</topic><topic>Proteins</topic><topic>Proto-Oncogene Proteins - analysis</topic><topic>Proto-Oncogene Proteins c-bcl-2 - analysis</topic><topic>Receptors, Estrogen - analysis</topic><topic>Receptors, Progesterone - analysis</topic><topic>Tumor Suppressor Protein p53 - analysis</topic><topic>Tumors</topic><topic>Uterine Neoplasms - metabolism</topic><topic>Uterine Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kounelis, Sophia</creatorcontrib><creatorcontrib>Kapranos, Nikiforos</creatorcontrib><creatorcontrib>Kouri, Efi</creatorcontrib><creatorcontrib>Coppola, Domenico</creatorcontrib><creatorcontrib>Papadaki, Helen</creatorcontrib><creatorcontrib>Jones, Mirka W</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Modern pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kounelis, Sophia</au><au>Kapranos, Nikiforos</au><au>Kouri, Efi</au><au>Coppola, Domenico</au><au>Papadaki, Helen</au><au>Jones, Mirka W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunohistochemical Profile of Endometrial Adenocarcinoma: A Study of 61 Cases and Review of the Literature</atitle><jtitle>Modern pathology</jtitle><stitle>Mod Pathol</stitle><addtitle>Mod Pathol</addtitle><date>2000-04-01</date><risdate>2000</risdate><volume>13</volume><issue>4</issue><spage>379</spage><epage>388</epage><pages>379-388</pages><issn>0893-3952</issn><eissn>1530-0285</eissn><coden>MODPEO</coden><abstract>The differences in immunohistochemical expression of p53, bcl-2, bax, estrogen receptor (ER), and progesterone receptor (PR) were evaluated in 40 endometrioid and 21 papillary serous carcinomas of endometrium and correlated with known predictors of survival, such as grade and stage. Uterine papillary serous adenocarcinomas (UPSA) showed significantly higher p53 expression than did uterine endometrioid adenocarcinomas (UEA) (76.2% versus 35%), whereas both ER and PR were more often positive in endometrioid than in serous tumors (p =.005 and.0005). No significant difference was found in bcl-2 and bax expression between both histologic types. However, there was definite decrease in intensity of bcl-2 in UPSA compared with UEA. In endometrioid carcinoma, p53 overexpression was associated with high-grade and advanced-stage tumors (p =.0006 and.006), whereas ER and PR expression was associated with low-grade and early-stage tumors (p =.0006 and.0001; p =.003 and.0006). Bcl-2 immunopositivity was more common in low-grade, early-stage rather than in high-grade, advanced-stage adenocarcinomas, but the difference was not statistically significant (p =.24 and.07). Bax immunopositivity was associated with well-differentiated (p =.04) and early-stage tumors. Furthermore, a significant inverse relationship between bax and p53 reactivity was defined (p =.05), especially in tumors of endometrioid type. Bax and PR immunoexpression correlated near the limit of statistical significance (p =.08), whereas no relationship was found among bax, bcl-2, and ER immunopositivity. Our results indicate that the differences in immunohistochemical profiles of endometrioid and serous carcinomas support the existence of different molecular pathways of their development. The correlation of immunohistochemical findings with histologic grade and clinical stage could help in predicting biologic behavior and planning treatment in patients who are diagnosed as having these tumors.</abstract><cop>New York</cop><pub>Elsevier Inc</pub><pmid>10786803</pmid><doi>10.1038/modpathol.3880062</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-3952 |
| ispartof | Modern pathology, 2000-04, Vol.13 (4), p.379-388 |
| issn | 0893-3952 1530-0285 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71072318 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
| subjects | Adenocarcinoma - metabolism Adenocarcinoma - pathology Apoptosis bax bcl-2 bcl-2-Associated X Protein Cancer therapies Cell death Cell growth Cystadenocarcinoma, Papillary - metabolism Cystadenocarcinoma, Papillary - pathology Endometrial adenocarcinoma Endometrial cancer Endometrial Neoplasms - metabolism Endometrial Neoplasms - pathology Endometrioid Endometrium Estrogens Female Humans Hyperplasia Immunohistochemistry Laboratory Medicine Medical prognosis Medicine Medicine & Public Health Neoplasm Staging original-article p53 Papillary serous Pathology Proteins Proto-Oncogene Proteins - analysis Proto-Oncogene Proteins c-bcl-2 - analysis Receptors, Estrogen - analysis Receptors, Progesterone - analysis Tumor Suppressor Protein p53 - analysis Tumors Uterine Neoplasms - metabolism Uterine Neoplasms - pathology |
| title | Immunohistochemical Profile of Endometrial Adenocarcinoma: A Study of 61 Cases and Review of the Literature |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T03%3A27%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunohistochemical%20Profile%20of%20Endometrial%20Adenocarcinoma:%20A%20Study%20of%2061%20Cases%20and%20Review%20of%20the%20Literature&rft.jtitle=Modern%20pathology&rft.au=Kounelis,%20Sophia&rft.date=2000-04-01&rft.volume=13&rft.issue=4&rft.spage=379&rft.epage=388&rft.pages=379-388&rft.issn=0893-3952&rft.eissn=1530-0285&rft.coden=MODPEO&rft_id=info:doi/10.1038/modpathol.3880062&rft_dat=%3Cproquest_cross%3E998331381%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=221143765&rft_id=info:pmid/10786803&rft_els_id=S0893395222040431&rfr_iscdi=true |